BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21573566)

  • 1. Combination therapy with a nuclear type-ii site agonist and 5-Fluorouracil - inhibition of mammary-tumor growth.
    Markaverich B; Schauweker T; Gregory R; Varma R; Varma M; Kittrell F; Medina D
    Int J Oncol; 1993 Mar; 2(3):385-92. PubMed ID: 21573566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
    Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
    Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
    Markaverich BM; Alejandro MA
    Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear type-ii [h-3] estradiol binding-sites in mcf-7 human breast-cancer cells - binding interactions with 2,6-bis-([3,4-dihydroxyphenyl]-methylene)cyclohexanone esters and inhibition of cell-proliferation.
    Markaverich B; Varma M; Densmore C; Tiller A; Schauweker T; Gregory R
    Int J Oncol; 1994 Jun; 4(6):1291-300. PubMed ID: 21567051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
    Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
    Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,6-Bis((3,4-dihydroxyphenyl)-methylene)cyclohexanone (BDHPC)-induced apoptosis and p53-independent growth inhibition: synergism with genistein.
    Attalla H; Mäkelä TP; Wähälä K; Rasku S; Andersson LC; Adlercreutz H
    Biochem Biophys Res Commun; 1997 Oct; 239(2):467-72. PubMed ID: 9344853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.
    Markaverich BM; Vijjeswarapu M
    Int J Biomed Sci; 2012 Dec; 8(4):219-32. PubMed ID: 23675277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
    Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
    J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth.
    Markaverich BM; Gregory RR; Alejandro MA; Varma RS; Johnson GA; Middleditch BS
    J Steroid Biochem; 1989 Nov; 33(5):867-76. PubMed ID: 2601331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II estrogen binding site agonist: synthesis and biological evaluation of the enantiomers of methyl-para-hydroxyphenyllactate (MeHPLA).
    Pretlow L; Williams R; Elliott M
    Chirality; 2003 Oct; 15(8):674-9. PubMed ID: 12923805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
    Kong L; Wang X; Zhang K; Yuan W; Yang Q; Fan J; Wang P; Liu Q
    PLoS One; 2015; 10(9):e0137888. PubMed ID: 26368019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
    Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
    Shen HJ; Wang YH; Xu J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):98-102. PubMed ID: 23714662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.
    Wang CZ; Li XL; Sun S; Xie JT; Aung HH; Tong R; McEntee E; Yuan CS
    Anticancer Res; 2009 Aug; 29(8):2927-32. PubMed ID: 19661297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
    Dun J; Chen X; Gao H; Zhang Y; Zhang H; Zhang Y
    Exp Biol Med (Maywood); 2015 Dec; 240(12):1672-81. PubMed ID: 25736303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
    van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.